Compare Crispr Therapeutics AG (CRSP) vs Lululemon Athletica Inc (LULU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Lululemon Athletica Inc — how do they compare? Crispr Therapeutics AG trades at $53.37 (market cap $4.88B), while Lululemon Athletica Inc trades at $94.4 (market cap $10.27B). The key difference: Lululemon Athletica Inc is far larger — about 2.1× Crispr Therapeutics AG's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Lululemon Athletica Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Lululemon Athletica Inc for 105 Days on average.
| CRSP | LULU | |
|---|---|---|
Market Cap | $4.88B | $10.27B |
Volume | 2,861,747 | 4,392,324 |
Sector | Health | Consumer Cyclical |
52-Week High | $74.92 | $215.88 |
52-Week Low | $44.34 | $91.88 |
Typical Hold Time | 77 Days | 105 Days |
Enterprise Value | $3.30B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
Lululemon stock trades at $94.5, down 54% year-to-date and near its 52-week low, reflecting a bearish technical trend. Despite strong profitability with a 12.78% net income margin and a low P/E of 7.63, the stock faces headwinds from recent revenue declines and multiple securities fraud investigations. Earnings have beaten estimates in recent quarters, but negative sentiment and governance concerns weigh on investor confidence.
The outlook remains cautious; the stock's deep discount to historical valuations presents a potential opportunity, but risks from legal probes, competitive pressures, and weak growth visibility suggest limited near-term upside. Analyst consensus is mixed with a $97.67 price target, indicating modest potential from current levels amid high uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →
